Ephedrine sulfate injection - Akorn

Drug Profile

Ephedrine sulfate injection - Akorn

Latest Information Update: 05 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Akorn
  • Class Antihypotensives; Decongestants; Propanolamines
  • Mechanism of Action Adrenergic receptor agonists; Alpha 1 adrenergic receptor agonists; Beta-adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypotension

Most Recent Events

  • 05 Apr 2017 Chemical structure information added
  • 16 Mar 2017 Launched for Hypotension in USA (IV) (Akorn website, March 2017)
  • 02 Mar 2017 Registered for Hypotension in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top